CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
OPERATING ACTIVITIES:
Net income	$ 32,901	$ 45,394
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	29,724	29,214
Non-cash impairment charges	0	2,754
Deferred income tax provision (benefit)	3,544	(1,234)
Share-based compensation	6,291	6,334
Amortization of debt issuance costs and expenses associated with debt refinancing	1,724	1,721
Non-cash lease expense	(17)	1,522
Loss on disposal of property and equipment	712	(2)
Gain from the sale of business	0	(42,876)
Change in fair value of contingent consideration and others	(765)	281
Changes in assets and liabilities:
Accounts receivable	(3,116)	16,756
Inventories	(11,561)	(2,332)
Prepaid expenses and other current assets	(5,046)	(3,574)
Other non-current assets	2,283	10,419
Accounts payable, accrued expenses and other current liabilities	(9,754)	14,449
Contract liabilities	0	(83)
Other non-current liabilities	(2,576)	(9,662)
Net cash provided by operating activities	44,344	69,081
INVESTING ACTIVITIES:
Purchases of property and equipment	(9,325)	(6,675)
Proceeds from sale of Extremity Orthopedics business	0	191,736
Acquired in-process research and development milestone	(4,742)	0
Cash paid for business acquisitions, net of cash acquired	0	(302,627)
Net cash used in investing activities	(14,067)	(117,566)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness	11,250	600
Payments on debt	(11,750)	(2,200)
Purchases of treasury stock	(125,000)	0
Proceeds from exercised stock options	1,239	2,222
Cash taxes paid in net equity settlement	(9,204)	(3,637)
Net cash used in financing activities	(133,465)	(3,015)
Effect of exchange rate changes on cash and cash equivalents	(3,168)	(9,690)
Net decrease in cash and cash equivalents	(106,356)	(61,190)
Cash and cash equivalents at beginning of period	513,448	470,166	$ 470,166
Cash and cash equivalents at end of period	$ 407,092	$ 408,976	$ 513,448